Milestone Pharmaceuticals is trading at $0.98, up 12.97% from the September 30 close of $0.87; no specific cause for the October 1 pre-market move has been identified. - The latest company release, dated September 24, reported enrollment of the first Canadian participant in its Phase 3 ReVeRA-301 trial. - Market context is mixed, and available evidence does not establish a broader-market or sector catalyst.